Late-Breaking Clinical Trial (LBCT) Submission Instructions

Submission Dates: Wednesday, Oct. 26 – Thursday, Dec. 8

All submitting authors must file disclosures before submitting your research on the ACC's Disclosure Website. Disclosures are only needed for yourself and the lead investigator. You will be asked to identify the lead investigator during the submission process. LBCT submissions will be considered “complete” without completed disclosures and will go to review as long as all other submission elements are complete. You do not need to take any action at this stage; ACC staff will contact coauthors separately to obtain these disclosures as a condition of submission. All disclosures need to be completed by December 19, 2016. Failure to provide disclosure information by the December 19, 2016 deadline will result in the removal of an accepted LBCT from the program.

The ACC employs a “single sign-on” process, which will improve the efficiency of the submission process. Please do not create a new ACC account if you already have one. Only one account is allowed per user in order to offer you high-quality services. Contact the Resource Center at or 800-253-4636, ext. 5603, if you are unsure whether you have an account.

Once you have signed in, the submitting author’s name and ID number will automatically prepopulate in the submission system; the name and ID number must match and are not editable. The submitting author’s name entered in the passgate system MUST be the author who will present the abstract/LBCT/case if selected. Notification of acceptance will be sent to this person.

  Entering LBCT Information
  Entering LBCT Information
  A. Title
  A. Title

  1. Do not bold, italicize, underline, superscript or subscript any items in the title.
  2. Do not include authors in the title. If you enter authors in the title, they will be removed.
  3. Do not include institutions in the title. If you enter institutions in the title, they will be removed.
  4. Do not use the “Enter” button in your title. This action will add hard returns, which are not allowed.
  5. Capitalize the first letter of all major words in the title except prepositions, articles, and conjunctions.
  6. Do not use abbreviations in the title. Abbreviations may be used in the abstract body.
  7. Do not end the title with a period.
  8. If the title contains more than one statement, use only one space after a period or colon.
  9. Do not use a comma before “and” in a series.
  10. Use a comma for number 1,000 and above.
  11. Substitute a colon for a dash/hyphen except when using prefixes.
  12. Do not use quotation marks in a title.
  13. Hyphenate the first prefix word when there is more than one prefix word used such as Non-Anti...
  14. For more information about title guidelines, see the Style and Editing Guidelines below.
  B. Categories
  B. Categories

  1. Select one category that is closest to the subject of your Late-Breaking Clinical Trial.
  2. Late-Breaking Clinical Trials submitted to a category that does not match the subject matter of the Late-Breaking Clinical Trial may be given a low score from reviewers.
  3. You will also be asked to indicate what kind of trial you are submitting:
    • Late-breaking clinical trial (major study)
    • Smaller study/randomized clinical trial (RCT)
    • Multicenter observational study or registry
    • Secondary analysis of major clinical trial
    • Other
  C. Keywords
  C. Keywords

  1. Select up to three keywords from the list of medical subject headings.
  2. Only one keyword is required.
  3. Leave unused/unneeded keyword fields blank.
  4. Do not enter the same keyword more than once.
  D. Institutions and Authors (Responsible Institutions)
  D. Institutions and Authors (Responsible Institutions)

  1. List the complete name including a full first name and initials. Multiple word first names should be placed in the “First Name” field.
  2. Please use English characters when entering names and eliminate any non-English characters such as tildes and umlauts.
  3. Do not include title, degrees, or suffix in the “Last Name” field.
  4. Do not enter more than one author in each “First Name” or “Last Name” field. If this is done, you will be contacted to correct this entry.
  5. If more than one abstract is submitted, please spell authors in exactly the same manner. This is important when indexing all authors in the online/mobile program planner systems.
  6. Use the author group field only for the name of an investigating team. This is typically something like “Investigators for ACC.” Do not use the author group to list individual authors. If this is done, you will be contacted to correct this entry. Authors entered as an “Author Group” will not be listed in the author index of the onsite programs.
  7. The author order is the order that authors will be listed in publications if the abstract is selected for presentation. The person who is expected to be the presenter does not need to appear as the first author.
  8. The contact information is not used as part of the institutions listed in any abstract publication. Institutions are entered in a separate area. \The submitting author will be notified about the outcome of the review and selection process.
  E. Late-Breaking Clinical Trials
  E. Late-Breaking Clinical Trials

Important Issues

  1. Late-breaking clinical trials MUST conform to specific size limits or they will remain in an incomplete status and will not be reviewed. Your abstract may not contain more than 1,900 characters, not including spaces. A graphic, or a table created with the table generator, equals 600 characters and is included as part of the 1,900 character limit.
  2. Use the standard Times New Roman font for text and Symbol font for symbols (DO NOT USE A THIRD-PARTY SYMBOL FONT!); any other fonts will not be accepted. Set all text as flush left, unjustified, and wrapping text as you type. Do NOT place hard returns at the end of each line.

Abstract Text

  1. You may type the body of the abstract directly into the space provided for the abstract body or upload this information from a file.
  2. Do not embed graphics or images in a file you intend to upload. They must be uploaded separately.
  3. You may include a table in the body of the abstract by uploading a document that has a table in it. This cannot be a table linked to spreadsheet.
  4. You may use five unique abbreviations in the body of the abstract. Spell out the complete phrase followed by the abbreviation in parentheses the first time the abbreviation is used. Abbreviations are not allowed in the title of the abstract.
  5. Do not include the title in the abstract body. The title will be collected in the Title Section.
  6. Do not include authors and institutions in the abstract body. This data will be collected in the Author Section.
  7. The abstract must be presented in the following sequence, using the headings listed (these headings have been setup in the abstract body text for you):

    Background: In an initial paragraph, provide relevant information regarding the background and purpose of the study, preferably in no more than one or two sentences.

    Methods: Briefly state the methods used.

    Results: Summarize the results in sufficient detail to support the conclusions.

    Conclusion: State the conclusions reached. It is not satisfactory to state “the results will be discussed.”

  8. Please proofread carefully for factual, spelling, and size errors. If published, the abstract will appear exactly as the online system confirmation shows.


  1. You may include a table in a file that you upload or create it online using the table generator.
  2. It is recommended you create the table in your word processing program, then use the file upload feature to transfer document to the abstract site. Table generation in a word processing program is much easier to accomplish than using the table generator.
  3. Do not embed a spreadsheet within your document. Even though it appears as a table, you will not be able to upload the file. You may copy the table from a spreadsheet and then paste it into the word processing program as a table instead of a linked spreadsheet. If you are not certain you have done this correctly, please contact technical support at (217) 398-1792.
  4. A table equals 600 characters and is included as part of the 1,900 character limit.


  1. Graphics should be high resolution and have a file type of “gif”, “jpg”, or “jpeg”. Even though the abstract system may allow you to upload a graphic with a different file type those graphics will not be reviewed or reproduced if the abstract is selected.
  2. Do not submit tables as graphics.
  3. Do not embed graphics or images in a file you intend to upload. Use the separate graphic upload feature if you wish to include a graphic/image.
  4. A graphic equals 600 characters and is included as part of the 1,900 character limit.
  When Is a Submission Considered Complete?
  When Is a Submission Considered Complete?
Submission is complete and ready for submission when, in the “Review My Work” section, you see the words “This submission is complete.” It is only submitted to reviewers after the deadline date. You may update or make changes to your Late Breaking Clinical Trial submission up until Thursday, December 8, 2016, 11:59 p.m. ET. The date your submission was last edited may be found in the Review My Work Section next to the words “Current Date/Time”. This will change each time there has been an alteration.
Revisions to your submission can be made until the date listed above. No changes will be accepted after this date. If any changes are made prior to the deadline, you must select “Review My Work” from the menu on the left. Make certain that you see the words “This submission is complete.” The presenting author may be changed if the abstract is selected for presentation during the invitation process by contacting ACC staff via email in mid-January.
  Disposition/Notification of Acceptance
  Disposition/Notification of Acceptance
You will be sent a notification with the status of your LBCT submission via email by Friday, January 20, 2017.
You are required to withdraw any other type of submission that is also accepted as an LBCT. Failure to do so will result in an embargo break, which would mean your LBCT could not be presented at the conference.

To withdraw a submitted ACC Abstract, Challenging Case (interventional cardiology), or Cardiovascular Team Case written notification (email or letter) must be sent to

To withdraw an LBCT or an FIT Clinical Decision-Making submission, notification must be sent to

To withdraw a YIA submission, written notification (email, fax, or letter) must be sent

This notification must include the title, authors and affiliations (as submitted), the control number, and the name, affiliation, phone, fax and e-mail of the submitter. We recommend using the summary page as part of this notification.
  Fee Schedule for Presenters
  Fee Schedule for Presenters
  1. There is a $35 (USD) nonrefundable processing fee for each abstract or Challenging Case submitted payable online by credit card only. Late-breaking clinical trial submitters must pay a $250 (USD) nonrefundable fee.
  2. If a person is both an abstract presenter and an invited speaker, the registration fee is waived.
  Logging onto the ACC Submission System
  Logging onto the ACC Submission System

Because you have read the ACC.17 Submission Instructions for using the web-based ACC abstract system, you are now ready to enter your submission. Begin your submission now.

Please save this page as a favorite in your Web browser so that you can quickly return to the submission system.

  Style and Editing Guidelines
  Style and Editing Guidelines
Always CAP










Do not CAP

(unless at the beginning of a title or after a colon)








de (French)









von (German)

One Word Includes











Two Words

Contrast Enhanced

Double Blind

Dual Chamber




Q Wave

Multi Vessel

Single Vessel

T Wave

Hyphenated Words






























ACC Logo
ACC.17 on Social Media:
2017 American College of Cardiology Foundation. Visit
Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Contact Us